Why is Beryl Drugs falling/rising?

As of 10-Sep, Beryl Drugs Ltd is currently priced at 24.16, reflecting a slight increase of 0.04 or 0.17%. Today's price summary indicates that the stock's performance is in line with its sector, although it is trading above the 20-day, 50-day, and 100-day moving averages, while being below the 5-day and 200-day moving averages. Despite a recent 1-week return of +0.37%, the stock has significantly underperformed over the past year with a return of -40.32%. The company has a Return on Capital Employed (ROCE) of 11, which suggests a very attractive valuation; however, its profits have decreased by 37% over the past year, contributing to a negative sentiment around the stock. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 60.89% compared to the 5-day average.
In the broader market context, the Sensex has increased by 1.06% over the past week, indicating that Beryl Drugs is lagging behind the benchmark. While the stock has shown a strong 3-year return of +202.00%, its long-term fundamentals are weak, with a poor EBIT to Interest ratio of 0.86 and slow growth in net sales and operating profit over the last five years. This underperformance is further highlighted by the stock's significant decline compared to the market's overall negative return of -2.89% in the last year. Overall, the combination of weak long-term fundamentals, declining investor interest, and substantial underperformance relative to the market suggests that the stock's recent price movement is influenced by negative factors outweighing the positive.